ensifentrine vs TQC3721
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: PDE3/PDE4 · full Chronic Obstructive Pulmonary Disease pipeline
ensifentrine · Ohtuvayre
Marketed by Merck & Co. and partners
NCT04542057 · Phase 3 · completed
This was a large (790-patient), randomized, quadruple-blinded, placebo-controlled Phase 3 trial with a hard clinical/lung-function primary endpoint (change in FEV1 area under the curve over 12 hours), and the ensifentrine group showed a statistically significant improvement over placebo on that primary comparison. The randomization, blinding, active placebo control, adequate sample size, and clear statistically significant result in the favorable direction together support a strong grade.
Next expected readout: March 2027 · NCT05270525 (registry estimate)
Reported efficacy
Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h (12 weeks): Placebo-corrected change from baseline in FEV1 AUC0-12h at Week 12: +110 mL for ensifentrine (p<0.0001) (met)
Result source: NCT05743075
TQC3721
Developed by AstraZeneca under a licence from Sino Biopharmaceutical
NCT06527144 · Phase 2 · completed
The trial randomized 240 participants to two TQC3721 doses or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinically relevant lung-function measure FEV1. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.
Next expected readout: February 2027 · NCT07464587 (registry estimate)
Reported efficacy
Change of the maximum value of Forced Expiratory Volume in the first second (FEV1) (From baseline to four weeks after treatment): Primary endpoint, change in peak FEV1 at week 4 vs placebo: 3 mg +100 mL (95% CI 41 to 159; P = .0011); 6 mg +147 mL (95% CI 93 to 201; P < .0001) (PACER-II, CHEST 2026). (met)
Result source: NCT06527144
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ensifentrine | TQC3721 |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not posted · NCT05743075 | —Trial running · NCT07147946 |
| Trough FEV1, change | -0.0 vs -0.0±0 vs placeboNCT0454205714 other results
| —Trial running · NCT07147946 |
| SGRQ total, change | -4.5 vs -4.1−0.5 vs placeboNCT045420575 other results
| —Trial running · NCT07147946 |
| TDI focal score | 1.9 vs 0.8+1.1 vs placeboNCT045359862 other results
| —Trial running · NCT07147946 |
Moderate or severe exacerbations, annualised rate
- ensifentrine
- —Not posted · NCT05743075
- TQC3721
- —Trial running · NCT07147946
Trough FEV1, change
- ensifentrine
- -0.0 vs -0.0±0 vs placeboNCT04542057
14 other results
- -0.0 vs -0.0 NCT04535986
- 0.0 vs -0.0 NCT04542057
- 0.0 vs -0.0 NCT04535986
- 0.0 vs -0.0 NCT04542057
- 0.0 vs -0.0 NCT04535986
- 0.0 vs -0.0 NCT03443414
- -0.0 vs -0.0 NCT03443414
- 0.2 vs 0.1 NCT03673670
- -0.0 vs -0.0 NCT03443414
- 0.2 vs 0.1 NCT03673670
- 0.0 vs -0.0 NCT03443414
- 0.0 vs -0.1 NCT04091360
- -0.0 vs -0.1 NCT04091360
- -0.1 vs -0.1 NCT04091360
- TQC3721
- —Trial running · NCT07147946
SGRQ total, change
- ensifentrine
- -4.5 vs -4.1−0.5 vs placeboNCT04542057
5 other results
- -6.2 vs -3.9 NCT04535986
- -4.0 vs -2.9 NCT04542057
- -5.7 vs -2.7 NCT04535986
- -3.6 vs -1.9 NCT04542057
- -6.2 vs -4.0 NCT04535986
- TQC3721
- —Trial running · NCT07147946
TDI focal score
- ensifentrine
- 1.9 vs 0.8+1.1 vs placeboNCT04535986
2 other results
- 1.6 vs 0.4 NCT04535986
- 1.3 vs 0.6 NCT04535986
- TQC3721
- —Trial running · NCT07147946
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ensifentrine: 4 of 4 rows · TQC3721: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ensifentrine |
|---|---|
| Dropout rate | 21.2%a NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 show 29 more results16.5%Ensifentrine NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 —From Week 24 to Week 48: Ensifentr NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 —Up to Week 24: Ensifentrine NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 10%3 mg BID NCT06460493 · Phase 3 · registry result, not featured evidence 0%3 mg NCT04091360 · Phase 2 · registry result, not featured evidence —3 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%6 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%1 mg NCT04091360 · Phase 2 · registry result, not featured evidence —1 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%0.30 mg NCT04091360 · Phase 2 · registry result, not featured evidence —0.30 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%0.10 mg NCT04091360 · Phase 2 · registry result, not featured evidence —3 mg NCT04027439 · Phase 2 · registry result, not featured evidence —3 mg NCT04027439 · Phase 2 · registry result, not featured evidence —6 mg NCT04027439 · Phase 2 · registry result, not featured evidence —1.5 mg NCT04027439 · Phase 2 · registry result, not featured evidence —1.5 mg NCT04027439 · Phase 2 · registry result, not featured evidence —0.50 mg NCT04027439 · Phase 2 · registry result, not featured evidence —0.50 mg NCT04027439 · Phase 2 · registry result, not featured evidence —0.15 mg NCT04027439 · Phase 2 · registry result, not featured evidence —0.15 mg NCT04027439 · Phase 2 · registry result, not featured evidence —6 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination —1.5 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination 7.3%3.0 mg NCT03443414 · Phase 2 · registry result, not featured evidence 6.3%6.0 mg NCT03443414 · Phase 2 · registry result, not featured evidence 3.7%1.5 mg NCT03443414 · Phase 2 · registry result, not featured evidence 13.4%0.75 mg NCT03443414 · Phase 2 · registry result, not featured evidence —Higher Dose Nebulised Treatment NCT03028142 · Phase 2 · registry result, not featured evidence —Lower Dose Nebulised Treatment NCT03028142 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 4.2%a NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 show 29 more results2.1%Ensifentrine NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 —From Week 24 to Week 48: Ensifentr NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 —Up to Week 24: Ensifentrine NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 —3 mg BID NCT06460493 · Phase 3 · registry result, not featured evidence —3 mg NCT04091360 · Phase 2 · registry result, not featured evidence —3 mg NCT04091360 · Phase 2 · registry result, not featured evidence —6 mg NCT04091360 · Phase 2 · registry result, not featured evidence —1 mg NCT04091360 · Phase 2 · registry result, not featured evidence —1 mg NCT04091360 · Phase 2 · registry result, not featured evidence —0.30 mg NCT04091360 · Phase 2 · registry result, not featured evidence —0.30 mg NCT04091360 · Phase 2 · registry result, not featured evidence —0.10 mg NCT04091360 · Phase 2 · registry result, not featured evidence —3 mg NCT04027439 · Phase 2 · registry result, not featured evidence —3 mg NCT04027439 · Phase 2 · registry result, not featured evidence —6 mg NCT04027439 · Phase 2 · registry result, not featured evidence —1.5 mg NCT04027439 · Phase 2 · registry result, not featured evidence —1.5 mg NCT04027439 · Phase 2 · registry result, not featured evidence —0.50 mg NCT04027439 · Phase 2 · registry result, not featured evidence —0.50 mg NCT04027439 · Phase 2 · registry result, not featured evidence —0.15 mg NCT04027439 · Phase 2 · registry result, not featured evidence —0.15 mg NCT04027439 · Phase 2 · registry result, not featured evidence —6 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination —1.5 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination 4.9%3.0 mg NCT03443414 · Phase 2 · registry result, not featured evidence 2.5%6.0 mg NCT03443414 · Phase 2 · registry result, not featured evidence 0%1.5 mg NCT03443414 · Phase 2 · registry result, not featured evidence 7.3%0.75 mg NCT03443414 · Phase 2 · registry result, not featured evidence —Higher Dose Nebulised Treatment NCT03028142 · Phase 2 · registry result, not featured evidence —Lower Dose Nebulised Treatment NCT03028142 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.6%a NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 show 29 more results—Ensifentrine NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 4.8%From Week 24 to Week 48: Ensifentr NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 6.7%Up to Week 24: Ensifentrine NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 0%3 mg BID NCT06460493 · Phase 3 · registry result, not featured evidence 0%3 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%3 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%6 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%1 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%1 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%0.30 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%0.30 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%0.10 mg NCT04091360 · Phase 2 · registry result, not featured evidence 0%3 mg NCT04027439 · Phase 2 · registry result, not featured evidence 0%3 mg NCT04027439 · Phase 2 · registry result, not featured evidence 0%6 mg NCT04027439 · Phase 2 · registry result, not featured evidence 0%1.5 mg NCT04027439 · Phase 2 · registry result, not featured evidence 0%1.5 mg NCT04027439 · Phase 2 · registry result, not featured evidence 0%0.50 mg NCT04027439 · Phase 2 · registry result, not featured evidence 0%0.50 mg NCT04027439 · Phase 2 · registry result, not featured evidence 0%0.15 mg NCT04027439 · Phase 2 · registry result, not featured evidence 0%0.15 mg NCT04027439 · Phase 2 · registry result, not featured evidence 1.4%6 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination 0%1.5 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination 1.2%3.0 mg NCT03443414 · Phase 2 · registry result, not featured evidence 1.3%6.0 mg NCT03443414 · Phase 2 · registry result, not featured evidence 2.5%1.5 mg NCT03443414 · Phase 2 · registry result, not featured evidence 2.5%0.75 mg NCT03443414 · Phase 2 · registry result, not featured evidence 0%Higher Dose Nebulised Treatment NCT03028142 · Phase 2 · registry result, not featured evidence 3.4%Lower Dose Nebulised Treatment NCT03028142 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a covid-19 3.2% (placebo 3.4%) headache 2% (placebo 2.4%) nasopharyngitis 1.8% (placebo 1%) NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 show 27 more resultsnasopharyngitis 2.6% (placebo 0%) headache 1.8% (placebo 2.9%) upper respiratory tract infection 1.8% (placebo 0%) NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 covid-19 3.4% (placebo 2.9%) headache 3.4% (placebo 2.9%) nasopharyngitis 2.7% (placebo 0%) NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 3 mg dermatitis contact 14.3% (placebo 0%) headache 14.3% (placebo 0%) catheter site bruise 0% (placebo 0%) NCT04091360 · Phase 2 · registry result, not featured evidence 3 mg catheter site bruise 4.3% (placebo 0%) haemoptysis 4.3% (placebo 0%) kidney infection 4.3% (placebo 0%) NCT04091360 · Phase 2 · registry result, not featured evidence 6 mg headache 28.6% (placebo 0%) contusion 14.3% (placebo 0%) nasopharyngitis 14.3% (placebo 0%) NCT04091360 · Phase 2 · registry result, not featured evidence 1 mg headache 16.7% (placebo 0%) catheter site bruise 0% (placebo 0%) contusion 0% (placebo 0%) NCT04091360 · Phase 2 · registry result, not featured evidence 1 mg dental caries 4.3% (placebo 0%) dysmenorrhoea 4.3% (placebo 0%) headache 4.3% (placebo 0%) NCT04091360 · Phase 2 · registry result, not featured evidence 0.30 mg nasopharyngitis 14.3% (placebo 0%) catheter site bruise 0% (placebo 0%) contusion 0% (placebo 0%) NCT04091360 · Phase 2 · registry result, not featured evidence 0.30 mg dizziness postural 4.2% (placebo 0%) dyspnoea 4.2% (placebo 4%) headache 4.2% (placebo 0%) NCT04091360 · Phase 2 · registry result, not featured evidence 0.10 mg copd 16.7% (placebo 4%) dry throat 16.7% (placebo 0%) syncope 16.7% (placebo 0%) NCT04091360 · Phase 2 · registry result, not featured evidence 3 mg atrioventricular block first degree 0% (placebo 0%) blood creatine phosphokinase increased 0% (placebo 0%) blood thyroid stimulating hormone increased 0% (placebo 0%) NCT04027439 · Phase 2 · registry result, not featured evidence 3 mg blood creatine phosphokinase increased 3% (placebo 0%) blood thyroid stimulating hormone increased 3% (placebo 0%) hypertension 3% (placebo 0%) NCT04027439 · Phase 2 · registry result, not featured evidence 6 mg atrioventricular block first degree 0% (placebo 0%) blood creatine phosphokinase increased 0% (placebo 0%) blood thyroid stimulating hormone increased 0% (placebo 0%) NCT04027439 · Phase 2 · registry result, not featured evidence 1.5 mg atrioventricular block first degree 14.3% (placebo 0%) blood creatine phosphokinase increased 0% (placebo 0%) blood thyroid stimulating hormone increased 0% (placebo 0%) NCT04027439 · Phase 2 · registry result, not featured evidence 1.5 mg blood thyroid stimulating hormone increased 6.3% (placebo 0%) hypertension 6.3% (placebo 0%) atrioventricular block first degree 0% (placebo 0%) NCT04027439 · Phase 2 · registry result, not featured evidence 0.50 mg atrioventricular block first degree 0% (placebo 0%) blood creatine phosphokinase increased 0% (placebo 0%) blood thyroid stimulating hormone increased 0% (placebo 0%) NCT04027439 · Phase 2 · registry result, not featured evidence 0.50 mg hypertension 6.1% (placebo 0%) urinary tract infection 6.1% (placebo 0%) blood creatine phosphokinase increased 3% (placebo 0%) NCT04027439 · Phase 2 · registry result, not featured evidence 0.15 mg atrioventricular block first degree 0% (placebo 0%) blood creatine phosphokinase increased 0% (placebo 0%) blood thyroid stimulating hormone increased 0% (placebo 0%) NCT04027439 · Phase 2 · registry result, not featured evidence 0.15 mg ear infection 2.9% (placebo 0%) hypertension 2.9% (placebo 0%) urinary tract infection 2.9% (placebo 0%) NCT04027439 · Phase 2 · registry result, not featured evidence 6 mg headache 6.8% (placebo 1.3%) ventricular extrasystoles 4.1% (placebo 0%) chronic obstructive pulmonary disease 2.7% (placebo 1.3%) NCT03673670 · Phase 2 · registry result, not featured evidence · combination 1.5 mg headache 6.7% (placebo 1.3%) ventricular extrasystoles 2.7% (placebo 0%) accelerated idioventricular rhythm 1.3% (placebo 0%) NCT03673670 · Phase 2 · registry result, not featured evidence · combination 3.0 mg headache 8.5% (placebo 3.8%) cough 7.3% (placebo 1.3%) hypertension 4.9% (placebo 1.3%) NCT03443414 · Phase 2 · registry result, not featured evidence 6.0 mg nasopharyngitis 6.3% (placebo 8.9%) headache 5% (placebo 3.8%) chronic obstructive pulmonary disease 3.8% (placebo 7.6%) NCT03443414 · Phase 2 · registry result, not featured evidence 1.5 mg chronic obstructive pulmonary disease 6.2% (placebo 7.6%) cough 4.9% (placebo 1.3%) headache 4.9% (placebo 3.8%) NCT03443414 · Phase 2 · registry result, not featured evidence 0.75 mg chronic obstructive pulmonary disease 4.9% (placebo 7.6%) cough 4.9% (placebo 1.3%) headache 4.9% (placebo 3.8%) NCT03443414 · Phase 2 · registry result, not featured evidence headache 18.5% (placebo 10.7%) arthralgia 3.7% (placebo 0%) catheter site bruise 3.7% (placebo 0%) NCT03028142 · Phase 2 · registry result, not featured evidence medical device site reaction 13.8% (placebo 14.3%) headache 6.9% (placebo 10.7%) chest discomfort 3.4% (placebo 7.1%) NCT03028142 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 26 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ensifentrine
show 17 more results
show 32 more results
show 5 more results
show 5 more results
show 14 more results
show 9 more results
show 5 more results
show 2 more results
show 1 more result
show 2 more results
show 2 more results
show 1 more result
+ 15 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ensifentrine's landscape · TQC3721's landscape